Results 71 to 80 of about 133,861 (300)

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

Arthritis &Rheumatology, EarlyView.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie, Victoria P. Werth, Eric Milliman, Kyle Ferber, Roland Brown, Jad Zoghbi, Nathalie Franchimont, Youmna Lahoud, Catherine Barbey   +8 more
wiley   +1 more source

Clinical recognition and management of alopecia in women of color,

International Journal of Women's Dermatology, 2019
Certain types of alopecia, such as traction alopecia, discoid lupus erythematosus, and central centrifugal cicatricial alopecia, occur more commonly in African-American individuals than in those of other ethnicities.
Jodie Raffi, BA, Raagini Suresh, BS, Oma Agbai, MD, FAAD   +2 more
doaj   +1 more source

Epidermal Interferon kappa drives cutaneous lupus‐like lesions, photosensitivity and systemic autoimmunity in vivo

Arthritis &Rheumatology, Accepted Article.
Objective Keratinocyte‐derived interferon kappa (IFN‐κ) is chronically overexpressed in human non‐lesional systemic lupus erythematosus (SLE) skin. Recent evidence suggests that epidermal signals instruct the immune system in SLE, but whether epidermal IFN‐κ alone is sufficient to drive lupus phenotypes has not been investigated.
Benjamin Klein, Deborah J. Colesa, Yiqing Gao, Patrick A. O'Brien, Lin Zhang, Lori Lowe, Kelsey E. McNeely, Nguyen Thi Kim Nguyen, Svenja Henning, Mehrnaz Gharaee‐Kermani, Jeffrey B. Hodgin, Jacob W. S. Martens, Johann E. Gudjonsson, Celine C. Berthier, J. Michelle Kahlenberg   +14 more
wiley   +1 more source

Heterogeneous lupus‐specific lesions and treatment outcome, in a single patient, over a period of time [PDF]

, 2019
The report highlights the importance of strict clinico-histological correlations when skin biopsies are performed in diagnostic doubt in systemic lupus erythematosus.
Agostini, Patrick, Fernandes, Melissa, Moraes-Fontes, Maria Francisca, Riso, Nuno, Taulaigo, Anna V., Vidal, Carolina   +5 more
core   +2 more sources

A randomized, placebo‐controlled trial of hydroxychloroquine in incomplete lupus

Arthritis &Rheumatology, Accepted Article.
Objectives Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity and incidence of SLE. Methods Hydroxychloroquine (HCQ) was chosen as an
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Low Dose Thalidomide for Treatment of Resistant Discoid Lupus Erythematosus. A Case Report [PDF]

, 2013
Discoid lupus erythematosus (DLE) is a chronic, indolent, disfiguring disease that is characterized by scaly, erythematous, disk-shaped patches and plaques followed by atrophy, scarring and depigmentation.
Campos, S, Lestre, S, Ponte, P
core  

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Barnes Hospital Bulletin [PDF]

, 1976
https://digitalcommons.wustl.edu/bjc_barnes_bulletin/1125/thumbnail ...

core   +1 more source

Clinical and immunopathological spectrum of immunoglobulin M pemphigoid: a multicenter case series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Pemphigoid diseases are primarily mediated by IgG or IgA autoantibodies against the cutaneous basement membrane zone (BMZ). Although recent observations suggest the existence of exclusively IgM‐mediated pemphigoid disease, a larger study is lacking.
Kaan Yilmaz, Stephanie Goletz, Christoph M. Hammers, Katharina Boch, Claudia Zeidler, Henning Wiegmann, Estelle Bergmann, Tina Rastegar Lari, Onur Dikmen, Nina Häring, Robert Strohal, Andreas Kleinheinz, Eva N. Hadaschik, Nina van Beek, Sonja Ständer, Enno Schmidt   +15 more
wiley   +1 more source

Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan [PDF]

, 2010
We investigated Patients with systemic lupus erythematosus with the objective of assessing whether early damage accrued in systemic lupus erythematosus as measured by the SLICC/ACR Damage Index predicts mortality in lupus Patients that have been followed
Ahmad, A., Ahmed, Bilal, Habib, H. B., Islam, M., Merchant, D., Rabbani, M. A., Shah, S. M. A., Tahir, S.   +7 more
core   +1 more source